BTX - BioTime, Inc.
1.0100 0.00 (0.00%)
After hours: 4:54PM EDT
| Previous Close | 1.0600 |
| Open | 1.0400 |
| Bid | 1.0100 x 1200 |
| Ask | 1.0600 x 800 |
| Day's Range | 1.0100 - 1.0700 |
| 52 Week Range | 0.6600 - 2.8100 |
| Volume | 298,932 |
| Avg. Volume | 553,848 |
| Market Cap | 151.139M |
| Beta (3Y Monthly) | 3.45 |
| PE Ratio (TTM) | 2.28 |
| EPS (TTM) | 0.4430 |
| Earnings Date | Mar 15, 2019 - Mar 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.83 |
- Simply Wall St.•3 days ago
Should You Be Excited About BioTime, Inc.'s (NYSEMKT:BTX) 35% Return On Equity?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- Simply Wall St.•10 days ago
Is Forbuild SA’s (WSE:BTX) 16% ROCE Any Good?
Today we'll look at Forbuild SA (WSE:BTX) and reflect on its potential as an investment. In particular, we'll consider...
- Thomson Reuters StreetEvents•last month
Edited Transcript of BTX earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 BioTime Inc Earnings Call
- Business Wire•last month
BioTime Announces Appointment of General Counsel
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, today announced that it has appointed Chase C. Leavitt as BioTime’s General Counsel and Corporate Secretary. “We’re extremely fortunate to have Chase join us and bring his extensive public company experience as well as a strong track record to the role of general counsel,” stated Brian M. Culley, Chief Executive Officer of BioTime.
- Simply Wall St.•last month
Don't Sell Forbuild SA (WSE:BTX) Before You Read This
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Motley Fool•last monthBioTime (BTX) Q1 2019 Earnings Call Transcript
BTX earnings call for the period ending March 31, 2019.
- Zacks•last month
Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1
Achillion (ACHN) reports narrower year-over-year loss in Q1. The absence of an approved product results in no revenues in the quarter.
- Business Wire•2 months ago
BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, has been awarded a new research & development grant for 2019 of up to 9 million Israeli New Shekels (approximately $2.5 million USD) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, the Company’s retinal pigment epithelium transplant therapy currently in Phase I/IIa development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. To date, the IIA has provided annual grants totaling approximately $15 million for the development of the OpRegen program.
- Zacks•2 months ago
BioTime (BTX) Tops Q1 Earnings and Revenue Estimates
BioTime (BTX) delivered earnings and revenue surprises of 600.00% and 40.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
BioTime: 1Q Earnings Snapshot
On a per-share basis, the Alameda, California-based company said it had profit of 30 cents. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- Business Wire•2 months ago
BioTime Reports First Quarter 2019 Financial Results and Provides Business Update
ALAMEDA, Calif.-- -- Positive OpRegen ® Data Presented at Association for Research in Vision and Ophthalmology Annual Meeting Announced Issuance of New Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury Entered Into Exclusive Collaboration with Orbit Biomedical Ltd. BioTime, Inc. , a clinical-stage biotechnology company developing cellular therapies for unmet medical ...
- Business Wire•2 months ago
BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet needs, announced today the issuance of a Notice of Allowance for a patent from the United States Patent and Trademark Office (USPTO) for United States Patent Application No. 15/156,316 for a method of reducing spinal cord injury (SCI)-induced parenchymal cavitation in patients that have suffered an acute spinal cord injury. The claimed method involves injecting oligodendrocyte progenitor cells (OPCs) derived from human pluripotent stem cells into the SCI site and covers both human embryonic and induced pluripotent stem cell-derived OPCs. “We believe OPC1 acts via several distinct mechanisms to aid the recovery of SCI patients, one of which is the prevention or reduction of cavitation, and we are pleased at having received an allowance on this important patent, which we believe further enhances our OPC1 cell therapy program,” stated Brian M. Culley, Chief Executive Officer of BioTime.
- Business Wire•2 months ago
BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, today announced that it will report its first quarter 2019 financial and operating results on Thursday, May 9th, 2019, following the close of the U.S. financial markets. BioTime management will also host a conference call and webcast on Thursday, May 9th, 2019, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2019 financial results and to provide a business update. Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere outside the U.S. and should request the “BioTime Inc. Call”.
- Zacks•2 months ago
Will BioTime (BTX) Report Negative Q1 Earnings? What You Should Know
BioTime (BTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•2 months ago
BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced that updated results from a Phase I/IIa clinical study of its lead product candidate, OpRegen®, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA), will be presented today at the 2019 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019) in Vancouver, BC, Canada. Data from the study demonstrate that treatment with OpRegen continues to be well tolerated and in some patients, signs of structural improvement in the treated areas of the retina have been observed.
- Benzinga•2 months ago
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Biotech stocks staged a recovery this week after being in the red in the previous two weeks. AbbVie Inc (NYSE: ABBV )'s psoriasis drug Skyrizi received FDA nod. The week also saw the release of strong ...
- Business Wire•2 months ago
BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy and Repair Conference
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that Edward D. Wirth, III, M.D., Ph.D., Chief Medical Officer of BioTime, will present at the 26th Annual American Society for Neural Therapy and Repair (ASNTR) Annual Conference on April 26th, 2019 at 10:30am EDT as part of Session 6: “Spinal Cord Injury”. Dr. Wirth’s presentation is entitled “Top-line 12-month Results from the SCiStar Study - A Phase 1/2a Trial of Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cells (OPC1) in Patients with Subacute Cervical Spinal Cord Injury”. “We believe the primary goals of the SCiStar Study, which were to observe the safety of OPC1 in cervical spinal cord injury patients as well as other important metrics including related to the optimal timing of OPC1 injection, tolerability of the immunosuppression regimen, engraftment of OPC1 cells, and rates of motor recovery observed among different study subpopulations, have all been successfully achieved,” stated Dr. Wirth.
- Simply Wall St.•2 months ago
Did Changing Sentiment Drive BioTime's (NYSEMKT:BTX) Share Price Down A Worrying 58%?
It is a pleasure to report that the BioTime, Inc. (NYSEMKT:BTX) is up 37% in the last quarter. But that is small recompense for the exasperating returns over three years. Tragically, the share price declined 58% in that ti...
- Business Wire•2 months ago
BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
BioTime, Inc. , a clinical-stage biotechnology company developing new cellular therapies, announced today that updated results from a Phase I/IIa clinical study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration with geographic atrophy, will be presented at the 2019 Association ...
- Zacks•2 months ago
BioTime (BTX) Upgraded to Strong Buy: Here's What You Should Know
BioTime (BTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- Zacks•3 months ago
Top Ranked Momentum Stocks to Buy for April 2nd
Top Ranked Momentum Stocks to Buy for April 2nd
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of BTX earnings conference call or presentation 14-Mar-19 8:30pm GMT
Q4 2018 BioTime Inc Earnings Call
- Business Wire•3 months ago
BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019
BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer, will be presenting at the Oppenheimer & Co.
- Associated Press•3 months ago
BioTime: 4Q Earnings Snapshot
The Alameda, California-based company said it had a loss of 35 cents per share. Losses, adjusted for non-recurring costs, came to 7 cents per share. The results met Wall Street expectations. The average ...
- Business Wire•3 months ago
BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
ALAMEDA, Calif.-- -- Completed Acquisition of Asterias Biotherapeutics, Inc. Completed Distribution of AgeX Therapeutics Shares to BioTime Shareholders Entered Into Exclusive Collaboration with Orbit Biomedical Ltd. BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, reported financial and operating results for the fourth quarter and full year ended December 31, ...
